Clinical trial NCT01212276: A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
Official title: A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Metastatic Melanoma
Malignant Metastatic Melanoma
Advanced Melanoma
Melanoma
Lead sponsor: Morphotek
Sponsor class: INDUSTRY
First posted: 2010-09-30
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.

Detailed description: Melanoma is a serious form of skin cancer. If untreated, the melanoma can spread beyond the original affected tissue and invade distant tissue and organs. Treatment for metastatic melanoma includes medical treatments (chemotherapy or immunotherapy), surgery, or radiation therapy. MORAb-028 is a recombinant human immunoglobulin M (IgM) monoclonal antibody that recognizes a cell surface diacyl ganglioside named disialoganglioside (GD2). GD2 is overexpressed in tumors of neuro-ectodermal origin such as melanomas, neuroblastomas, small-cell lung carcinomas, and many sarcomas, while absent in most normal tissues. GD2 expression has been demonstrated in human melanoma and small cell lung cancer by thin layer chromatography and radiolabeled anti-GD2 antibody detection. It is hypothesized that one mode of action of MORAb-028 is complement-dependent cytotoxicity. Complement-dependent cytotoxicity is a mechanism for killing tumor cells in which an antibody bound to the target cell surface fixes complement, which results in assembly of the complement membrane attack complex that punches holes in the target cell membrane resulting in subsequent cell lysis. IgMs strongly bind to C1Q and robustly activate complement-dependent cytotoxicity. MORAb-028 is being developed as a potential therapy for GD2-positive tumors.

Eligibility criteria: Inclusion Criteria:

* Measurable metastatic melanoma that has failed standard therapy
* Males and females greater than or equal to 18 years of age
* Life expectancy of greater than or equal to 3 months

Exclusion Criteria:

* Significant cardiovascular impairment
* Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results
* Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028

Primary outcomes:
measure: Safety of single dose radio labeled MORAb-028 in subjects with metastatic melanoma
timeFrame: Daily for 7 days followed by weekly for 2 weeks, then biweekly for 4 weeks
Secondary outcomes:
measure: Radiologic distribution of a single i.v. infusion of MORAb-028
timeFrame: Daily for 1 week post study drug administration
measure: Pharmacokinetic parameters of labeled and unlabeled MORAb-028
timeFrame: Daily for 7 days followed by weekly for 2 weeks, then biweekly for 4 weeks
measure: The incidence of human antihuman antibody formation
timeFrame: Week 2 and Week 8
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
Study officials:
affiliation: Morphotek
name: Christina Coughlin, MD, PhD
role: STUDY_DIRECTOR
affiliation: Memorial Sloan Kettering Cancer Center
name: Jorge Carrasquillo, MD
role: PRINCIPAL_INVESTIGATOR
References: